abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Esta página não está disponível em Português e está sendo exibida em English

Artigo

6 Jan 2014

Author:
Ravinder Gabble & Jillian Clare Kohler, in Global Health (USA)

To patent or not to patent? the case of Novartis’ cancer drug Glivec in India

Glivec...produced by the pharmaceutical company Novartis, is prescribed [to treat]...one of the most common blood cancers in eastern countries...[T]he Supreme Court of India gave its final decision...rejecting the appeal of the Swiss...drug manufacturer...[T]he Supreme Court stated that even if the bioavailability of the drug was improved, it did not demonstrate enhanced efficacy and that Glivec was not patentable...[T]he drug needs to be taken lifelong…For this reason, along with the fact that 95% of Indians do not possess private health insurance, its pricing plays a critical factor in cancer patients’ ability to access a continuous supply of Glivec for effective treatment...The pricing of cancer treatment is arguably the most important factor in determining India’s position in the case: a monthly dose of the patented version of Glivec…is over three times an average Indian’s annual income...

Linha do tempo